Bavi 3mg/kg reached 13.1 months overall survival, finally adjusted to 11.7 months survival in the phase2 second-line NSCLC trial. Docetaxel reached 5.6 months.
These data were achieved in a less healthy patient population: (ECOG) ≤ 2.
Had some “agent” not engineered the sabotage of the phase 2 trial, we would certainly have had Bavi FDA approved and on the market back in 2012-2013.
Bavi worked as expected then, and it has performed as expected again.
BAVI WORKS.
In the healthier SUNRISE patient population we definitely should see better survival in both arms.
For Docetaxel the longest previous survival, in the healthier patient population (ECOG) ≤ 0 or 1, was 10.4 months. How DRAMATIC were the recent survival data? 11 months?? better?
If Bavi performed at 13 months, 14 months or better in this healthier patient group, Rob Garnick should now be able to get the FDA approval for Bavi plus Doce in 2nd line NSCLC.
As always, no safety issues were flagged. SUNSTAR
So, Peregrine can now start up the Bavi/Durva immuno combination trials ..... BUT WHERE IS THE MANAGEMENT COMING OUT WITH ANY POSITIVE INFORMATION DEFENDING THE DRUG PIPELINE AND COMPANY IN THE FACE OF A 71% DROP IN 2016 .... WHERE IS IR, SK, JAY, RG, ET AL ......
Bull-markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria .. Sir John Templeton
Make your Life a Mission .... NOT an Intermission. † §|PL1|§
